Updated findings from the dose-optimization part of a first-in-human phase 1 trial (NCT05599984) showed that ABBV-706, a seizure-related homolog prote...

At the Society of Hematological Oncology 2025 Annual Meeting, CancerNetwork® spoke with Sanam Loghavi, MD, following her role in a discussion titled “...

The clinical implications of defining a cure in multiple myeloma will shift the treatment landscape such that patients only require a finite number of...

Osimertinib (Tagrisso) plus chemotherapy exhibited a statistically significant and clinically meaningful overall survival (OS) improvement vs osimerti...

Neoadjuvant pembrolizumab (Keytruda) plus chemotherapy followed by surgery and adjuvant pembrolizumab improved various response and survival outcomes...

Pirtobrutinib (Jaypirca) demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) comp...

Ivonescimab plus carboplatin/pemetrexed elicited a significant and clinically meaningful progression-free survival (PFS) advantage vs placebo plus car...

Zidesamtinib elicited an objective response rate (ORR) of 44% (95% CI, 34%-53%) and a complete response (CR) rate of 1% in patients with advanced ROS1...

A clinically meaningful reduction in relapse rates was found with nivolumab (Opdivo)/chemotherapy vs chemotherapy alone in patients with completely re...

Efficacy was not improved with concomitant durvalumab (Imfinzi) during chemotherapy and radiation (RT) for patients with stage III unresectable non-sm...